PIK3CA and breast cancer: Moreover, PIK3CA mutations have been recently included in the tier IA of genomic alterations in BC, of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), as predictors of benefit from a-selective PI3Kis.